Products
Efalizumab Biosimilar Monoclonal Antibody (CD11a) for Research
Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a[1] subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-166-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody |
| INN Name | Efalizumab |
| Target | ITGAL |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 3eo9:HL/3eoa:HL:BA/3eob:HL:BA |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2001 |
| Year Recommended | 2002 |
| Companies | Genentech;Merck Serono;XOMA |
| Conditions Approved | Psoriasis |
| Conditions Active | na |
| Conditions Discontinued | Psoriatic arthritis;Type 1 diabetes mellitus |
| Development Tech | na |
About target - ITGAL
1. Protein Integrin alpha-L
2. Gene ITGAL
3. Organism Homo sapiens (Human)
Function
Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R (PubMed:11812992, PubMed:15528364).
Integin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:29100055).
Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity (PubMed:15356110).
Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992).
Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis (By similarity).
Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590).
